Print Page

Products found to contain undeclared medicines

The United States: Bethel Nutritional Consulting, Inc. issues nationwide voluntary recall of B-Lipo Capsules due to the presence of an undeclared drug ingredient Lorcaserin
Bethel Nutritional Consulting, Inc. is recalling one lot of B-Lipo Capsules to the consumer level (Lot no. 20213). The firm was informed by the US Food and Drug Administration (FDA) that a sample of B-Lipo Capsules collected and tested by the FDA was found to contain Lorcaserin, a controlled substance used for weight loss.

Adverse health consequences associated with taking Lorcaserin range from difficulty thinking, hallucinations, and feeling of intense excitement to changes in blood sugar and heart rate. More serious adverse events, which may be life-threatening, include damage to the heart valve, or serotonin syndrome particularly if Lipo-B is taken with other medications that work similarly. Excessive levels of serotonin can cause symptoms that range from mild (shivering and diarrhea) to severe (muscle stiffness, fever, and seizures). Severe serotonin syndrome can be fatal if not treated. No illnesses or injuries have been reported to the company to date in connection with this product.

The product was sold directly to individual customers in our New York City sales office and to consumers online at The company has discontinued distribution of this product.

Consumers should not consume B-Lipo Capsules and should return it immediately to the place of purchase. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking this product.

Please refer to the following website in FDA for details:

In Hong Kong, the above product is not a registered pharmaceutical product.

Ends/ Saturday, 20 December 2014
Issued at HKT 12:00